MARKET

URGN

URGN

Urogen Pharma
NASDAQ
14.50
+0.04
+0.28%
After Hours: 14.50 0 0.00% 16:00 03/18 EDT
OPEN
14.50
PREV CLOSE
14.46
HIGH
14.58
LOW
13.83
VOLUME
294.59K
TURNOVER
0
52 WEEK HIGH
24.13
52 WEEK LOW
7.75
MARKET CAP
494.77M
P/E (TTM)
-4.0892
1D
5D
1M
3M
1Y
5Y
UroGen: All Eyes On UGN-102
UroGen's JELMYTO revenues are growing but not by enough to support its operations. UroGen will launch UGN-102 in treatment of bladder cancer in Q1, 2025. The company's lead therapy has limited potential but is the primary driver of its future.
Seeking Alpha · 18h ago
UroGen Pharma Price Target Maintained With a $54.00/Share by HC Wainwright & Co.
Dow Jones · 19h ago
Weekly Report: what happened at URGN last week (0311-0315)?
Weekly Report · 19h ago
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Benzinga · 19h ago
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)
TipRanks · 19h ago
UroGen Pharma Price Target Cut to $34.00/Share From $35.00 by Oppenheimer
Dow Jones · 3d ago
UroGen Pharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 3d ago
Oppenheimer Maintains Outperform on UroGen Pharma, Lowers Price Target to $34
Benzinga · 3d ago
More
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Webull offers Urogen Pharma Ltd stock information, including NASDAQ: URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading URGN stock methods without spending real money on the virtual paper trading platform.